
    
      This study is designed primarily to obtain information on the preliminary efficacy, safety
      and immunogenicity of ACAM-CDIFFâ„¢ vaccine, as compared to placebo in subjects who are
      experiencing their first event of CDI and are being treated with the antibiotic standard of
      care. This study will be conducted in the United States and United Kingdom. Adult subjects
      with limited chronic disease, who are currently receiving treatment for their first episode
      of CDI will be enrolled in this trial. Subjects will be required to be able to take oral
      antibiotics.
    
  